India's API Market Set for 5-7% Growth Through FY28
Synopsis
India's API market, valued at $15-16 billion, is on track for 5-7% annual growth through FY28. Key drivers include government support and a shift towards complex APIs, promising a more robust pharmaceutical landscape.
Key Takeaways
India's API market valued at $15-16 billion.
Projected growth of 5-7% in FY27 and FY28.
Shift towards high-potency and complex APIs.
Government initiatives and bulk drug parks are crucial.
Growth driven by aging population and healthcare access.
New Delhi, March 2 (NationPress) The active pharmaceutical ingredient (API) sector in India, currently estimated to be worth approximately $15–16 billion, is anticipated to expand at a compound annual growth rate of 5–7 percent in FY27 and FY28, according to a report released on Monday.
The analysis from CareEdge Ratings indicates that this growth will be fueled by supportive government policies, a transition towards high-potency and complex APIs, increasing domestic demand, and enhanced access to both regulated and emerging markets.
Indian pharmaceutical companies are evolving from basic APIs to more complex formulations to mitigate price reductions, enhance profit margins, and maintain customer loyalty, the report highlights.
The report also pointed out ongoing dependence on China for essential starting materials, yet it expressed hope that government-backed initiatives and Production-Linked Incentive-supported bulk drug parks will start yielding positive results.
"While it may take time for these measures to fully manifest, signs of progress are already visible: over 30 projects have been completed, with numerous companies launching new capacities under this initiative," the ratings agency reported.
In addition, a range of high-potent and complex APIs is being developed, with their commercial launch expected in the upcoming years, indicating India's gradual advancement up the value chain.
Substantial growth from this transition is predicted to occur in 2-4 years, as most related projects have yet to reach commercial viability and significant production scale-up, the report forecasts.
"In the long term, growth is likely to be driven by an aging population, improved healthcare access, increased insurance coverage, rising chronic diseases, loss of exclusivity, and expansion into additional emerging markets," remarked Pritesh Rathi, Assistant Director at CareEdge Ratings.
Government-supported bulk drug parks are poised to influence the next phase of API investments, with nearly 80 percent of ongoing projects tied to this initiative. Notable developments include large-scale facilities valued between $20 billion and $40 billion in Andhra Pradesh, Himachal Pradesh, and Gujarat, aimed at bolstering domestic API production, decreasing reliance on imports, and driving cost efficiencies across the sector.
Point of View
The report highlights a significant opportunity for growth within India's pharmaceutical sector. With strategic government support and an evolving market landscape, the API sector is well-positioned to enhance its global competitiveness, ultimately benefiting the healthcare system and economy.
NationPress
2 May 2026
Frequently Asked Questions
What is the current value of India's API market?
India's API market is currently valued at approximately $15–16 billion.
What is the projected growth rate for FY27 and FY28?
The market is expected to grow at a compound annual growth rate of 5–7 percent.
What factors are driving the growth of India's API market?
Key factors include favorable government policies, a shift towards complex APIs, and increasing domestic demand.
What role do bulk drug parks play in the API sector?
Bulk drug parks, supported by the government, are expected to significantly influence API investments and production capabilities.
When can we expect substantial growth from the current projects?
Meaningful growth is anticipated to materialize in about 2-4 years as projects reach commercialization.
